The Research Of The Effect And Relationship Of E-cadherin And Lysyl Oxidase-like2in The Invasion And Metastasis Of Cholangiocarcinoma

Objective:To explore the expression of E-cadherin and LOXL2in cholangiocarcinoma, and analyzed their relationship with the patient’s gender, age, histological, clinical stage, lymph node metastasis, tissue and organ transfer and the relationship between the two factors in the invasion and metastasis of cholangiocarcinoma.Method:Streptavidin peroxidase (SP) and SYBR Green real-time polymerase chain reation (RT-PCR) were used to detect protein and mRNA of E-cadherin and LOXL2in47cases of cholangiocarcinoma,47adjacent cholangiocarcinoma, and20cases of normal bile duct.Results:①The positive expression of E-cadherin protein was21.3%in cholangiocarcinoma,74.5%in adjacent cholangiocarcinoma, and95.0%in normal bile duct. The expression of E-cadherin protein was significantly lower in cholangiocarcinoma than that in adjacent cholangiocarcinoma and normal bile duct (P<0.05). The positive expression of LOXL2protein was68.1%in cholangiocarcinoma,10.6%in adjacent cholangiocarcinoma, and10.0%in normal bile duct.. The expression of LOXL2protein was significantly lower in cholangiocarcinoma than that in adjacent cholangiocarcinoma and normal bile duct(P<0.05).②The positive expression of E-cadherin mRNA was [0.0796(0.0396,0.1282)] in cholangiocarcinoma,[1.0831(0.2191,1.3758)] in adjacent cholangiocarcinoma, and [1.1796(0.9692,1.2676)] in normal bile duct. The expression of E-cadherin mRNA was significantly lower in cholangiocarcinoma than that in adjacent cholangiocarcinoma and normal bile duct (P<0.05). The positive expression of LOXL2mRNA was [8.1769(0.5351,15.6202)] in cholangiocarcinoma,[0.5796(0.3923,0.8356)] in adjacent cholangiocarcinoma, and [0.5067(0.2194,0.7413)] in normal bile duct.. The expression of LOXL2mRNA was significantly higher in cholangiocarcinoma than that in adjacent cholangiocarcinoma and normal bile duct (P<0.05).③The ralationship of the expression of E-cadherin and LOXL2with the clinicopathological parameters of cholangiocarcinoma pationts:We have compared the expression of E-cadherin and LOXL2in the well-differentiated group and the poorly differentiated group, the I-II phase group and the III-IV phase group, the group with lymph node metastasis and the group without lymph node metastasis, the group with tissue and organ metastasis and the group without tissue and organ metastasis, the statistical difference was significant (P<0.05), but in the younger than60years of age group and the older than60years and equal to60years of age group, the male group and the female group, the intrahepatic bile duct group, the hilar bile duct group and the common bile duct group, the statistical difference was not significant (P>0.05).④The expression of E-cadherin protein was negatively related to that of LOXL2protein (r=-0.358, P=0.013).⑤The expression of E-cadherin mRNA was negatively related to that of LOXL2mRNA (r=-0.464, P=0.001).Conclusion:①The expression of E-cadherin was reduced in cholangiocarcinoma. The lower the degree of tumor differentiation,the higher the tumor stage, and with lymph node metastasis and tissue and organ metastasis, the lower the expression of E-cadherin.②The expression of LOXL2was increased in cholangiocarcinoma. The lower the degree of tumor differentiation,the higher the tumor stage, and with lymph node metastasis and tissue and organ metastasis, the higher the expression of LOXL2.③Both the down-regulation of E-cadherin and the up-regulation of LOXL2were related to the occurrence and development of the invasion and metastasis of cholangiocarcinoma.